March 05, 2018
Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial
In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Read the full article in The American of Tropical Medicine and Hygiene.
More from CNAS
-
It’s Time for a True Industrial Strategy for American National Security
Commentary
For an industrial strategy to work, the president must make it a White House priority that pulls together all elements of national power....
By Becca Wasser & Mara Rudman
-
Sharper: Allies and Partners
Commentary
Amid intensifying geopolitical challenges, the United States is finding new ways to address security issues by cultivating and strengthening alliances and partnerships. How ca...
By Gwendolyn Nowaczyk & Charles Horn
-
How We Survive Ep 5: Wargames
Podcast
Dr. Ed McGrady, Adjunct Senior Fellow for the Defense Program at CNAS, joins the show to discuss how climate began to factor into humanitarian crisis war games as far back as ...
By Dr. ED McGrady
-
Wars Are Not Accidents
Commentary
The road to conflict is an action-reaction process. Leaders decide whether and how to respond to a rival’s moves, and they often search for ways to lower the temperature. Esca...
By Erik Lin-Greenberg
